iTonic gets Nasdaq 180-day bid price extension

iTonic Holdings Ltd received a 180-day extension from Nasdaq, until October 19, 2026, to regain compliance with Nasdaq’s minimum closing bid price requirement under Listing Rule 5550(a)(2).

Rhea-AI Filing Summary

iTonic Holdings Ltd received a 180-day extension from Nasdaq, until October 19, 2026, to regain compliance with Nasdaq’s minimum closing bid price requirement under Listing Rule 5550(a)(2). The company previously exhausted an initial 180-day compliance period that ended on April 20, 2026.

If iTonic does not meet the minimum bid price rule by the new deadline, Nasdaq may delist its Class A ordinary shares. iTonic could then request a review of any delisting determination by a Nasdaq Hearings Panel. The company continues to describe itself as a healthcare solution provider focused on brachytherapy treatment planning systems.

Positive

• None.

Negative

• iTonic remains out of compliance with Nasdaq’s Minimum Bid Price Rule, and failure to regain compliance by October 19, 2026 could lead to a delisting notice for its Class A ordinary shares.

Insights

Equity market structure analyst

Nasdaq’s 180-day extension keeps iTonic listed for now but highlights ongoing bid-price noncompliance and potential delisting risk.

Nasdaq’s approval of an additional 180-day period, ending on October 19, 2026, confirms that iTonic Holdings Ltd is currently below the minimum closing bid price required by Nasdaq Listing Rule 5550(a)(2). The company now has more time to lift its share price to the threshold level.

If the minimum bid price is not restored by the deadline, Nasdaq has indicated it would issue a delisting notice for the Class A ordinary shares. iTonic may then request a review by a Nasdaq Hearings Panel, but the outcome and timing would depend on that process and any further company actions.

Key Figures

Extension length: 180-calendar days New compliance deadline: October 19, 2026 Initial period end: April 20, 2026 +1 more

4 metrics

Extension length 180-calendar days Additional compliance period granted by Nasdaq

New compliance deadline October 19, 2026 Date by which minimum bid price must be regained

Initial period end April 20, 2026 End of first 180-day bid price compliance window

Founding year 1998 Year iTonic Holdings Ltd was founded

Key Terms

Minimum Bid Price Rule, Nasdaq Listing Rule 5550(a)(2), foreign private issuer, brachytherapy, +1 more

5 terms

Minimum Bid Price Rule regulatory

"to regain compliance with the minimum closing bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)"

A minimum bid price rule is a stock market requirement that a listed company's share must trade above a set minimum price over a specified period to remain listed on an exchange. It matters to investors because falling below that threshold can trigger warnings, potential delisting, and reduced liquidity—similar to a student needing a passing grade to stay enrolled—making the shares harder to buy, sell, or value accurately.

Nasdaq Listing Rule 5550(a)(2) regulatory

"minimum closing bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)"

foreign private issuer regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

brachytherapy medical

"focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment"

Brachytherapy is a form of radiation treatment where small radioactive sources are placed directly into or next to a tumor, delivering focused energy to kill cancer cells while sparing nearby healthy tissue. Think of it like using a localized heat lamp instead of heating an entire room. For investors, brachytherapy matters because it drives demand for specialized medical devices, treatment centers, and insurance coverage decisions, and can influence clinical outcomes that affect market adoption.

forward-looking statements regulatory

"This announcement contains forward-looking statements."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did iTonic Holdings Ltd (ITOC) announce regarding its Nasdaq listing?

iTonic announced that Nasdaq approved an additional 180-day extension, until October 19, 2026, for the company to regain compliance with the Minimum Bid Price Rule. This keeps its shares listed while it works to meet the required minimum closing bid price.

What is the Nasdaq Minimum Bid Price Rule affecting iTonic (ITOC)?

The Minimum Bid Price Rule under Nasdaq Listing Rule 5550(a)(2) requires listed companies to maintain a minimum closing bid price for their shares. iTonic is currently below this threshold and has been granted extra time to restore its share price to compliant levels.

How long is iTonic’s new extension period from Nasdaq?

Nasdaq granted iTonic a further 180-calendar day extension, running until October 19, 2026. This follows an initial 180-day compliance period that ended on April 20, 2026, during which the company did not successfully regain bid price compliance.

What happens if iTonic (ITOC) fails to regain Nasdaq bid price compliance by October 19, 2026?

If iTonic does not meet the Minimum Bid Price Rule by October 19, 2026, Nasdaq has stated it will issue written notification that the company’s Class A ordinary shares will be delisted. iTonic may then request a review before a Nasdaq Hearings Panel.

What business is iTonic Holdings Ltd (ITOC) engaged in?

iTonic, through Beijing Feitian Zhaoye Technology Co., Ltd., focuses on healthcare solutions for brachytherapy, a targeted radiation cancer therapy. Its lead Treatment Planning System is designed to support safe, effective brachytherapy using internal radioactive sources to treat malignant tumors.

Does iTonic’s announcement include any financial results or earnings data?

The announcement centers on Nasdaq granting iTonic an additional 180-day extension to satisfy the Minimum Bid Price Rule. It does not present revenue, earnings, or other financial performance figures, instead focusing on the company’s listing status and business description.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/23/2026 - 04:15 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April, 2026

Commission File Number: 001-42263

iTonic Holdings Ltd

Room 306, NET Building

Hong Jun Ying South Road, Chaoyang District

Beijing, China 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Exhibits

Exhibit No.		Description
99.1		Press Release

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	iTonic Holdings Ltd
Date: April 23, 2026	By:	/s/ Jianfei Zhang
	Name:	Jianfei Zhang
	Title:	Chief Executive Officer and Chairman of the Board of Directors

2

Exhibit 99.1

iTonic Holdings Ltd Granted An Extension of Additional 180-Day by
Nasdaq to Regain Compliance with Minimum Bid Price Rule

BEIJING, China, April 23, 2026 – iTonic Holdings Ltd (the “Company” or “ITOC”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today announced that on April 21, 2026, it received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that Nasdaq approved the Company’s request for an extension of additional 180-calendar day, or until October 19, 2026 (the “Extension”) to regain compliance with the minimum closing bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”).The Extension follows the expiration the initial 180-calendar day compliance period on April 20, 2026.

If the Company does not regain compliance with the Minimum Bid Price Rule by October 19, 2026, Nasdaq has informed the Company that it will provide written notification that the Company’s Class A ordinary shares will be delisted. At that time, the Company may request a review of the delisting determination by a Nasdaq Hearings Panel.

About iTonic Holdings Ltd

Founded in 1998, iTonic Holdings Ltd, through its wholly owned operating subsidiary, Beijing Feitian Zhaoye Technology Co., Ltd., focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its lead product, Beijing Feitian’s Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors. iTonic Holdings Ltd is committed to leveraging its products and services to establish a potential new standard of care across multiple malignant tumor applications. For more information, please visit: http://www.ftzy.com.cn/ir.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995, including but not limited to statements related to ITOC’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. These forward-looking statements can be identified by terminology such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “hope,” “going forward,” “intend,” “ought to,” “plan,” “project,” “potential,” “seek,” “may,” “might,” “can,” “could,” “will,” “would,” “shall,” “should,” “is likely to” and the negative form of these words and other similar expressions. Among other things, statements that are not historical facts, including statements about the Company’s beliefs and expectations are or contain forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. All information provided in this press release is as of the date of this press release and is based on assumptions that the Company believes to be reasonable as of this date, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

iTonic Holdings Ltd

Investor Relations

Email: ir@ftzy.com.cn

Lambert by LLYC

Jackson Lin

Phone: +1-646-717-4593

Email: jian.lin@llyc.global

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 6.5 KB